Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes
Elizabeth M. Garry(Aetion (United States)), Saira Jan(Rutgers, The State University of New Jersey), William Murk(Yale University), Aditya Rajan(AstraZeneca (United States)), E. V. CHEEVER(Aetion (United States)), Hannah Jang(Unity Health System), David Gambino(Horizon Blue Cross Blue Shield of New Jersey), Jeremy A. Rassen(Aetion (United States)), Sara Eapen(Aetion (United States)), Sebastian Schneeweiß(Brigham and Women's Hospital), Elizabeth Rubin(Horizon Blue Cross Blue Shield of New Jersey), Natalia Petruski‐Ivleva(AVEO Oncology (United States))
Cited by 18
Related Papers
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study
|European Journal of Clinical Pharmacology|2002|274
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
|Annals of Internal Medicine|2019|215
Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
|Alimentary Pharmacology & Therapeutics|2009|214
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
|Annals of the Rheumatic Diseases|2023|95